Gene Liau's most recent trade in Stoke Therapeutics Inc was a trade of 30,497 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Oct. 16, 2020.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 30,497 | 96,069 | - | - | Employee Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 16 Oct 2020 | 30,497 | 43,997 (0%) | 0% | 0.6 | 18,298 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 37.64 per share. | 16 Oct 2020 | 24,775 | 20,725 (0%) | 0% | 37.6 | 932,578 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 38.42 per share. | 16 Oct 2020 | 7,225 | 13,500 (0%) | 0% | 38.4 | 277,586 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 16 Oct 2020 | 5,851 | 13,500 (0%) | 0% | 40.0 | 234,042 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 5,851 | 126,566 | - | - | Employee Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 16 Oct 2020 | 5,851 | 19,351 (0%) | 0% | 0.6 | 3,511 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 1,503 | 70,386 | - | - | Employee Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 16 Oct 2020 | 1,503 | 45,500 (0%) | 0% | 2.2 | 3,292 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 1,649 | 132,417 | - | - | Employee Stock Option (right to buy) | |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 13 Oct 2020 | 1,649 | 15,149 (0%) | 0% | 0.6 | 989 | Common Stock |
| Stoke Therapeutics Inc | Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 13 Oct 2020 | 1,649 | 13,500 (0%) | 0% | 40 | 65,960 | Common Stock |